Citigroup: TONGCHENGTRAVEL (00780) has a stable financial outlook, maintains a "buy" rating.
The management of Tongcheng Travel does not see any significant changes in the industry regulatory environment, and will seek opportunities to collaborate with AI chatbot applications in order to strengthen its market position in the era of artificial intelligence.
Citigroup's research report stated that it has adjusted the profit forecast for TONGCHENGTRAVEL (00780) for the next two years, with a target price of 28 Hong Kong dollars and a maintained "buy" rating. This is because the group's valuation is only 10 times the forecasted P/E ratio for 2026, and its financial prospects are stable. TONGCHENGTRAVEL's management has not seen any significant changes in the industry regulatory environment and will seek opportunities to cooperate with AI chatbot applications to consolidate its market position in the era of artificial intelligence.
The report stated that TONGCHENGTRAVEL's performance in the fourth quarter of last year was roughly in line with expectations. Looking ahead to 2026, the bank expects the hotel room's night volume to continue to maintain a healthy level of high single-digit year-on-year growth; the average daily room rate (ADR) at hotels will also see a good industry recovery; the growth in transportation ticketing business will benefit more from value-added services and optimized subsidy policies, thereby enhancing profitability; other business income is expected to achieve strong growth through the integration of Wanda Hotels and further expansion of the hotel management chain network.
Related Articles

Morgan Stanley: Short-term pressure on Haidilao (06862) is an opportunity for absorption. Target price is 21.5 Hong Kong dollars.

Caterpillar Inc. (CAT.US) countersues Doosan Bobcat, patent war escalates, impacting North American market landscape.

Building Shanghai Fosun Pharmaceutical (02196) growth new cornerstone through financial report penetrating value, innovation drugs, and globalization double engine.
Morgan Stanley: Short-term pressure on Haidilao (06862) is an opportunity for absorption. Target price is 21.5 Hong Kong dollars.

Caterpillar Inc. (CAT.US) countersues Doosan Bobcat, patent war escalates, impacting North American market landscape.

Building Shanghai Fosun Pharmaceutical (02196) growth new cornerstone through financial report penetrating value, innovation drugs, and globalization double engine.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


